Deciphera Pharmaceuticals focuses on developing innovative therapies for cancer treatment, particularly through their proprietary drug discovery platform that specializes in switch-control kinase inhibitors. These inhibitors are designed to target the switch pocket region of kinases, which are crucial enzymes that regulate various cellular functions. By addressing the dysregulation of kinases that contribute to cancer progression, Deciphera aims to create more effective and durable treatment options. Their approach is patient-inspired, emphasizing the need to improve treatment outcomes for individuals living with cancer.

One of the key products developed by Deciphera is Ripretinib, an orally administered switch-control kinase inhibitor specifically engineered for the treatment of gastrointestinal stromal tumors (GIST). This drug is designed to inhibit a broad spectrum of mutations in the KIT and PDGFRA kinases, which are often responsible for disease progression and resistance to existing therapies. The company has demonstrated a commitment to advancing its pipeline of differentiated drug candidates, with a focus on addressing the mechanisms of tumor and drug resistance that limit the effectiveness of current cancer treatments. Through their innovative platform and ongoing clinical studies, Deciphera aims to make a significant impact on the lives of cancer patients.

United States

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing immunokinase inhibitors comprising vimseltinib (DCC-3014) that is in Phase 1b/2 clinical trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase 1b/2 clinical trial to treat metastatic solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, it is developing DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. The company serves in the United States and Europe. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Cancer

Digestive System Diseases

Hematologic Diseases

Deciphera Pharmaceuticals 

Gastrointestinal stromal tumors

Ripretinib is a tyrosine kinase inhibitor that inhibits KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet derived growth factor receptor A (PDGFRA) kinase, including wild type, primary, and secondary mutations. Ripretinib also inhibits other kinases in vitro, such as PDGFRB, TIE2, VEGFR2, and BRAF.
<a href="https://www.deciphera.com/uspi/qinlockuspi.pdf">Source</a>

Qinlock (ripretinib) (KIT & PDGFRA inhibitor) 

Tenosynovial Giant Cell Tumors

DCC-3014 is an investigational orally administered, potent and highly &nbsp;selective inhibitor of CSF1R. DCC-3014 was designed to selectively bind &nbsp;to the CSF1R switch pocket. DCC-3014 has greater than 100-fold &nbsp;selectivity for CSF1R over the closely related kinases FLT3, KIT, &nbsp;PDGFRα, PDGFRß and VEGFR2 and has an even greater selectivity for CSF1R &nbsp;over approximately 300 other human kinases. CSF1R is believed to control &nbsp;the differentiation and function of macrophages, a type of white blood &nbsp;cell that is programmed to either activate the immune system to fight &nbsp;cancer cells (so-called M1 macrophages) or programmed to inactivate the &nbsp;immune system and promote tumor growth (so-called M2 macrophages). &nbsp;Pro-tumoral M2 macrophages, also known as Tumor Associated Macrophages &nbsp;(TAMs), infiltrate certain tumors suppressing a natural immune response &nbsp;that would otherwise eradicate the tumor; a process known as macrophage &nbsp;checkpoints. In preclinical animal studies, DCC-3014 reduced these &nbsp;pro-tumoral M2 macrophages, inhibiting this immunosuppressive macrophage &nbsp;checkpoint.
<a href="https://www.deciphera.com/pipeline/dcc-3014/">Source</a>

Vimseltinib (DCC-3014) (CSF1R inhibitor)

Qinlock (Ripretinib)

Solid tumor/s

DCC-3116 in an investigational, orally administered, potent, and highly selective switch-control inhibitor of the ULK kinase that was discovered using our proprietary drug discovery platform. DCC-3116 is designed to inhibit autophagy, a key tumor survival mechanism in cancer cells, by inhibiting the ULK 1/2 kinases, which have been shown to be the initiating factors that activate autophagy. DCC-3116 in combination with RAS/MAP kinase signaling pathway inhibition has the potential to change the treatment of RAS/RAF cancers.

DCC-3116 (Inhibitor of ULK) + trametinib, sotorasib & binimetin

DCC-3116 (Inhibitor of ULK)+Qinlock

Colorectal cancer

DCC-3116 (Inhibitor of ULK)+encorafenib & cetuximab

Vimseltinib (DCC-3014) (CSF1R inhibitor) 

Rebastinib is an investigational, orally administered, potent, and &nbsp;selective inhibitor of the TIE2 kinase, the receptor for angiopoietins, &nbsp;an important family of vascular growth factors. TIE2 has an important &nbsp;role in regulating tumor angiogenesis, invasiveness, metastasis, and &nbsp;immunotolerance. In addition, there is a distinct population of &nbsp;pro-tumoral M2 macrophages in which TIE2 is active, known as TIE2 &nbsp;expressing macrophages (TEMs).
<a href="https://www.deciphera.com/pipeline/rebastinib/">Source</a>

Deciphera Pharmaceuticals

Company Details